{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T07:17:28Z","timestamp":1785655048259,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2025.10.003","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:54:19Z","timestamp":1760280859000},"page":"193.e1-193.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcome of Defibrotide Treatment for Severe Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehun","family":"Kwag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2025.10.003_bib0001","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.003_bib0002","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.003_bib0003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","article-title":"Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD)","volume":"54","author":"Yoon","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.003_bib0004","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.003_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.003_bib0006","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bmt.2009.349","article-title":"Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome","volume":"45","author":"Lee","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.003_bib0007","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bmt.2013.101","article-title":"Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?","volume":"48","author":"Yoon","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.003_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.003_bib0009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00062752-200311000-00010","article-title":"Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment","volume":"10","author":"Wadleigh","year":"2003","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.003_bib0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41409-022-01900-6","article-title":"Real-world use of defibrotide for veno-occlusive disease\/sinusoidal obstruction syndrome: the DEFIFrance Registry Study","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.003_bib0011","article-title":"Final long-term results from the Defifrance registry study: efficacy and safety of defibrotide for the treatment of severe\/very severe veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic cell transplantation","volume":"138","author":"Mohty","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.003_bib0012","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41409-021-01215-y","article-title":"Incidence and risk factors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1","volume":"56","author":"Yoon","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.003_bib0013","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cncr.31874","article-title":"Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia","volume":"125","author":"Yoon","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.003_bib0014","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12185-010-0649-y","article-title":"Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and\/or co-morbidities","volume":"92","author":"Lee","year":"2010","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.003_bib0015","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-0609.2011.01697.x","article-title":"Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities","volume":"87","author":"Lee","year":"2011","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.003_bib0016","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bmt.2016.171","article-title":"Comparable outcomes between younger (40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning","volume":"51","author":"Shin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.003_bib0017","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25257","article-title":"Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: prospective de-escalation study of TBI and ATG dose","volume":"93","author":"Lee","year":"2018","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.jtct.2025.10.003_bib0018","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.003_bib0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.14727","article-title":"Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation","volume":"178","author":"Richardson","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","article-title":"The use of defibrotide in blood and marrow transplantation","volume":"2","author":"Richardson","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.003_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/17512433.2018.1421943","article-title":"Defibrotide sodium for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"11","author":"Richardson","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.003_bib0022","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.003_bib0023","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/bloodadvances.2021005410","article-title":"Defibrotide: real-world management of veno-occlusive disease\/sinusoidal obstructive syndrome after stem cell transplant","volume":"6","author":"Nauffal","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.003_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1498782","article-title":"Operational procedure sharing pathway in veno-occlusive disease: a Delphi consensus-based recommendations","volume":"15","author":"Bonifazi","year":"2025","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.003_bib0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41409-024-02215-4","article-title":"Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"59","author":"Ichikawa","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.003_bib0026","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2014.168","article-title":"Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen","volume":"49","author":"Tsirigotis","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.003_bib0027","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.003_bib0028","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1705528","article-title":"Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT)","volume":"38","author":"Ramasamy","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.003_bib0029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","article-title":"Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens","volume":"11","author":"Radich","year":"1993","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.003_bib0030","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.003_bib0031","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.003_bib0032","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3904\/kjim.2021.082","article-title":"Hepatic sinusoidal obstruction syndrome\/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea","volume":"36","author":"Yoon","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jtct.2025.10.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211066176","article-title":"Hepatic venoocclusive disease\/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy [e-pub ahead of print]","volume":"12","author":"Lee","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.003_bib0034","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s44313-025-00077-3","article-title":"Atypical features of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after inotuzumab ozogamicin in adult patients with acute lymphoblastic leukemia","volume":"60","author":"Sung","year":"2025","journal-title":"Blood Res"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.003_bib0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","article-title":"Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin","volume":"27","author":"Simon","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.003_bib0036","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","article-title":"Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"37","author":"Imran","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.003_bib0037","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.1990.tb02583.x","article-title":"Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation","volume":"74","author":"Gluckman","year":"1990","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.003_bib0038","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","article-title":"Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.003_bib0039","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Tay","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9823","key":"10.1016\/j.jtct.2025.10.003_bib0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.003_bib0041","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2352-3026(23)00011-X","article-title":"Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial","volume":"10","author":"Grupp","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.003_bib0042","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2141.1993.tb03152.x","article-title":"A phase I\/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation","volume":"84","author":"Bearman","year":"1993","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.003_bib0043","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3346\/jkms.2006.21.5.897","article-title":"Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children","volume":"21","author":"Song","year":"2006","journal-title":"J Korean Med Sci"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:24:29Z","timestamp":1771374269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666636725014848"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcome of Defibrotide Treatment for Severe Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}